Immunic Unveils New Data on Vidofludimus Calcium at MSToronto2026

  • Immunic to present four abstracts on vidofludimus calcium at MSToronto2026, October 21-23, 2026.
  • CALLIPER Phase 2 open-label extension data show maintained disability outcomes through Week 48.
  • Preclinical data suggests vidofludimus calcium promotes neuronal survival via Nurr1 activation.
  • EBV-related immune activity linked to cognitive performance in progressive MS patients.
  • New disability endpoint proposed to capture both worsening and improvement in progressive MS.

Immunic's presentations at MSToronto2026 highlight the growing evidence base for vidofludimus calcium's differentiated profile in MS. The data suggests potential advantages in both inflammatory control and neuroprotection, addressing key unmet needs in progressive MS. With Phase 3 trials ongoing for relapsing MS and planned for progressive MS, Immunic is positioning itself as a key player in the oral MS therapy space. The company's ability to demonstrate sustained clinical benefits will be critical for its valuation and competitive positioning.

Clinical Validation
Whether the Phase 2 CALLIPER extension data will support progression to Phase 3 trials in progressive MS.
Mechanistic Differentiation
How Immunic's Nurr1 activation and DHODH inhibition dual mechanism will position vidofludimus calcium against competitors.
Regulatory Pathway
The pace at which Immunic can secure approvals for vidofludimus calcium in both relapsing and progressive MS indications.